INmune Bio, Inc. (NASDAQ:INMB) Short Interest Update

INmune Bio, Inc. (NASDAQ:INMB) was the recipient of a large decline in short interest in September. As of September 30th, there was short interest totalling 2,680,000 shares, a decline of 15.2% from the September 15th total of 3,160,000 shares. Based on an average daily volume of 218,600 shares, the days-to-cover ratio is presently 12.3 days.

INmune Bio Stock Performance

Shares of NASDAQ INMB traded up $0.38 during midday trading on Wednesday, hitting $5.21. 131,428 shares of the stock traded hands, compared to its average volume of 156,234. The firm has a 50-day moving average of $6.02 and a two-hundred day moving average of $8.21. The firm has a market capitalization of $103.06 million, a P/E ratio of -2.68 and a beta of 1.85. INmune Bio has a one year low of $4.78 and a one year high of $14.74.

INmune Bio (NASDAQ:INMB) last released its quarterly earnings results on Thursday, August 1st. The company reported ($0.50) earnings per share for the quarter, beating the consensus estimate of ($0.63) by $0.13. INmune Bio had a negative return on equity of 103.56% and a negative net margin of 26,333.59%. Equities analysts forecast that INmune Bio will post -2.14 earnings per share for the current fiscal year.

Insider Transactions at INmune Bio

In related news, CFO David J. Moss purchased 7,690 shares of the company’s stock in a transaction dated Thursday, September 12th. The shares were purchased at an average cost of $6.38 per share, with a total value of $49,062.20. Following the transaction, the chief financial officer now directly owns 1,275,869 shares in the company, valued at $8,140,044.22. This trade represents a 0.00 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In other INmune Bio news, CFO David J. Moss acquired 10,000 shares of the stock in a transaction that occurred on Monday, September 30th. The shares were acquired at an average cost of $5.29 per share, with a total value of $52,900.00. Following the transaction, the chief financial officer now owns 1,285,869 shares of the company’s stock, valued at $6,802,247.01. The trade was a 0.00 % increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CFO David J. Moss acquired 7,690 shares of the stock in a transaction that occurred on Thursday, September 12th. The stock was acquired at an average cost of $6.38 per share, for a total transaction of $49,062.20. Following the completion of the transaction, the chief financial officer now directly owns 1,275,869 shares in the company, valued at $8,140,044.22. This represents a 0.00 % increase in their position. The disclosure for this purchase can be found here. Insiders have purchased a total of 33,070 shares of company stock valued at $200,087 in the last ninety days. 35.20% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On INmune Bio

Several hedge funds and other institutional investors have recently modified their holdings of the company. Fermata Advisors LLC lifted its holdings in shares of INmune Bio by 6.9% during the 1st quarter. Fermata Advisors LLC now owns 31,451 shares of the company’s stock valued at $370,000 after buying an additional 2,025 shares during the period. Westside Investment Management Inc. lifted its holdings in shares of INmune Bio by 31.8% during the 2nd quarter. Westside Investment Management Inc. now owns 45,340 shares of the company’s stock valued at $400,000 after buying an additional 10,950 shares during the period. Rhumbline Advisers bought a new position in shares of INmune Bio during the 2nd quarter valued at $121,000. Bank of New York Mellon Corp increased its stake in shares of INmune Bio by 124.6% in the 2nd quarter. Bank of New York Mellon Corp now owns 58,600 shares of the company’s stock worth $517,000 after purchasing an additional 32,511 shares in the last quarter. Finally, Marshall Wace LLP increased its stake in shares of INmune Bio by 332.1% in the 2nd quarter. Marshall Wace LLP now owns 115,916 shares of the company’s stock worth $1,022,000 after purchasing an additional 89,091 shares in the last quarter. 12.72% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several research firms recently issued reports on INMB. Raymond James began coverage on INmune Bio in a research report on Friday, September 27th. They issued an “outperform” rating and a $18.00 price objective on the stock. Scotiabank began coverage on INmune Bio in a research report on Thursday, August 22nd. They issued a “sector outperform” rating and a $22.00 price objective on the stock.

INmune Bio Company Profile

INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.